Zai Lab (NASDAQ:ZLAB - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.19), Zacks reports. The firm had revenue of $109.07 million for the quarter, compared to the consensus estimate of $110.15 million. Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Zai Lab updated its FY 2025 guidance to EPS.
Zai Lab Stock Performance
Shares of NASDAQ ZLAB traded down $2.91 during mid-day trading on Monday, reaching $31.73. The company had a trading volume of 1,536,211 shares, compared to its average volume of 889,028. Zai Lab has a one year low of $13.48 and a one year high of $36.60. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of -11.45 and a beta of 1.02. The business's 50-day simple moving average is $27.67 and its 200 day simple moving average is $25.96.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Bank of America reiterated a "neutral" rating and set a $36.10 price objective (up previously from $29.00) on shares of Zai Lab in a research report on Monday. Cantor Fitzgerald upgraded Zai Lab to a "strong-buy" rating in a research report on Wednesday, February 5th.
Get Our Latest Stock Analysis on ZLAB
Insider Buying and Selling
In other Zai Lab news, insider Rafael Amado sold 7,583 shares of Zai Lab stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the transaction, the insider now owns 33,834 shares in the company, valued at $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 13.88% of the stock is owned by company insiders.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
See Also
Before you consider Zai Lab, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zai Lab wasn't on the list.
While Zai Lab currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
